Your shopping cart is currently empty

HC-070 is a TRPC5 and TRPC4 antagonist (IC50 = 9.3 nM and 46 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $81 | - | In Stock | |
| 5 mg | $172 | - | In Stock | |
| 10 mg | $263 | - | In Stock | |
| 25 mg | $452 | - | In Stock | |
| 50 mg | $636 | - | In Stock | |
| 100 mg | $858 | - | In Stock | |
| 200 mg | $1,150 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $177 | - | In Stock |
| Description | HC-070 is a TRPC5 and TRPC4 antagonist (IC50 = 9.3 nM and 46 nM). |
| Targets&IC50 | TRPC5 (human):9.3 nM, TRPC4 (human):46 nM |
| In vitro | HC-070 inhibits hTRPC5 currents activated via muscarinic type 1 (IC50 = 2.0 nM) and suppresses hTRPC4 currents via muscarinic type 2 (IC50 = 0.49 nM). In whole-cell manual patch clamp, HC-070 inhibits lanthanum-activated hTRPC5-, mTRPC5-, rTRPC5-mediated currents (IC50s of 0.52 nM, 0.55 nM, and 0.32 nM). In the amygdala slices, HC-070 (20 nM) decreases CCK-4-evoked neuronal activity. HC-070 weakly inhibits TRPC3 (IC50 = 1 μM) and blocks M2R-activated human TRPC1/TRPC4 channels (IC50 = 1.3 nM) and La3+- and M1R-activated human TRPC1/5 channels (IC50 = 1.4 nM and 4.4 nM)[1]. |
| In vivo | HC-070 (1 mg/kg) reduces the increased capacity for fear memory in mice subjected to chronic social stress on days 1-15. HC-070 (1 mg/kg, p.o.) affects mice with increased CCK-4-evoked anxiety. HC-070 (0.3-3 mg/kg, p.o.) causes a reduction of anxiety in a standard EPM. HC-070 (0.3-10 mg/kg, p.o.) reduces the time of immobility in a tail suspension test without impacting locomotor activity in mice. HC-070 (1-10 mg/kg, p.o.) reduces marble-burying behavior[1]. |
| Synonyms | HC 070 |
| Molecular Weight | 475.32 |
| Formula | C22H20Cl2N4O4 |
| Cas No. | 1628291-95-1 |
| Smiles | Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O |
| Relative Density. | 1.46 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (105.19 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.